Evercore ISI resumed coverage on AmerisourceBergen with a new price target
$ABC
Other Pharmaceuticals
Health Care
Evercore ISI resumed coverage of AmerisourceBergen with a rating of Outperform and set a new price target of $185.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/31/2023 | $185.00 | Buy | Citigroup |
| 1/31/2023 | $185.00 | Outperform | Evercore ISI |
| 10/11/2022 | $160.00 → $169.00 | Neutral → Buy | BofA Securities |
| 8/22/2022 | Equal-Weight | Morgan Stanley | |
| 7/11/2022 | $150.00 | Outperform → In-line | Evercore ISI |
| 6/7/2022 | $167.00 → $178.00 | Hold → Buy | Deutsche Bank |
| 5/26/2022 | Equal Weight → Overweight | Barclays | |
| 4/12/2022 | $178.00 | Overweight → Equal-Weight | Morgan Stanley |
SC 13G - Cencora, Inc. (0001140859) (Subject)
SC 13G/A - Cencora, Inc. (0001140859) (Subject)
SC 13G/A - AMERISOURCEBERGEN CORP (0001140859) (Subject)
4 - Cencora, Inc. (0001140859) (Issuer)
4 - Cencora, Inc. (0001140859) (Issuer)
4 - Cencora, Inc. (0001140859) (Issuer)
Citigroup initiated coverage of AmerisourceBergen with a rating of Buy and set a new price target of $185.00
Evercore ISI resumed coverage of AmerisourceBergen with a rating of Outperform and set a new price target of $185.00
BofA Securities upgraded AmerisourceBergen from Neutral to Buy and set a new price target of $169.00 from $160.00 previously
8-K - Cencora, Inc. (0001140859) (Filer)
8-K - Cencora, Inc. (0001140859) (Filer)
FWP - Cencora, Inc. (0001140859) (Subject)
Revenue of $66.9 billion for the Third Quarter, an 11.5 Percent Increase Year-Over-Year Third Quarter GAAP Diluted EPS of $2.35 and Adjusted Diluted EPS of $2.92 Adjusted Diluted EPS Guidance Range Raised to $11.85 to $11.95 for Fiscal 2023 Company will begin operating as Cencora and trading under the ticker symbol "COR," effective August 30, 2023 AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2023 third quarter ended June 30, 2023, revenue increased 11.5 percent year-over-year to $66.9 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.35 for the third quarter of fiscal 2023 compare
AmerisourceBergen Corporation (NYSE:ABC) today announced that it plans to release its results for the Third Quarter of Fiscal 2023 on Wednesday, August 2, 2023, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on August 2, 2023. Participating in the conference call will be: Steven H. Collis, Chairman, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Financial Officer The live call will be webcast via the Company's website at investor.amerisourcebergen.com. Users are encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled st
Revenue of $63.5 billion for the Second Quarter, a 9.9 Percent Increase Year-Over-Year Second Quarter GAAP Diluted EPS of $2.13 and Adjusted Diluted EPS of $3.50 Adjusted Diluted EPS Guidance Range Raised to $11.70 to $11.90 for Fiscal 2023 AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2023 second quarter ended March 31, 2023, revenue increased 9.9 percent year-over-year to $63.5 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.13 for the second quarter of fiscal 2023 compared to $2.59 in the prior year second quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that
AmerisourceBergen Corporation (NYSE:ABC) today announced that its Board of Directors has elected Werner Baumann and Lauren M. Tyler as new independent directors, effective October 1, 2023. With the election of Mr. Baumann and Ms. Tyler, the Board of Directors will increase from ten to twelve members, ten of whom are independent. "We look forward to welcoming Mr. Baumann and Ms. Tyler to AmerisourceBergen's Board of Directors. Their experience at preeminent multinational companies and unique perspectives will complement our Board's skill sets and help oversee the company's long-term, sustainable growth," said Mark Durcan, Lead Independent Director. "Werner and Lauren's expertise in their
Transaction Highlights Walgreens Boots Alliance announces the sale of shares of AmerisourceBergen Corporation pursuant to prepaid variable share forward transactions executed through a registered public offering for current proceeds of approximately $1.6 billion and, depending on the stock price at the time, potentially additional proceeds at maturity, along with a concurrent share repurchase by AmerisourceBergen of approximately $250 million Prepaid variable share forward transactions provide liquidity while maintaining ability to participate in potential stock price appreciation Proceeds to Walgreens Boots Alliance will be used primarily for debt paydown and general corporate pur
AmerisourceBergen Corporation (NYSE:ABC) (the "Company") announced today a registered public offering of 10.5 million shares of common stock of the Company in connection with Walgreens Boots Alliance Holdings LLC (the "Selling Stockholder") entering into prepaid variable share forward transactions (the "variable forward transactions") relating to the Company's common stock with certain counterparties (the "counterparties"). The Company has been advised that, in order to establish their initial hedge positions with respect to the variable forward transactions, the counterparties or their affiliates will borrow an aggregate of 7,293,548 shares of the Company's common stock from third-party
VALLEY FORGE, Pa.--(BUSINESS WIRE)--AmerisourceBergen Corporation (NYSE: ABC) today announced that its Board of Directors declared a quarterly dividend of $0.44 per common share, payable March 1, 2021, to stockholders of record at the close of business on February 12, 2021. About AmerisourceBergen AmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care. Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the pharmaceutical supply chain. Global manufacturers depend on us for services that drive commercial success for their products. Through our dail